Characteristics | No Response (n = 53) | Moderate Response (n = 38) | Good Response (n = 22) | p |
---|---|---|---|---|
Age (yrs) | 65.1 ± 12.7 | 66.2 ± 15.3 | 68.0 ± 12.2 | NS |
Disease duration (mo) | 166 ± 143 | 115 ± 108 | 171 ± 157 | NS |
Morning stiffness (min) | 278 ± 369 | 171 ± 323 | 195 ± 413 | NS |
No. of tender joints | 10.2 ± 6.1 | 8.6 ± 4.6 | 9.9 ± 8.2 | NS |
No. of swollen joints | 9.0 ± 4.3 | 7.3 ± 4.8 | 7.0 ± 3.9 | NS |
Visual analog scale (mm) | 56.5 ± 18.6 | 66.5 ± 21.0 | 54.6 ± 24.5 | NS |
C-reactive protein (mg/dl) | 2.8 ± 2.6 | 1.5 ± 1.6 | 2.2 ± 2.6 | NS |
Erythrocyte sedimentation rate (ESR, mm/h) | 60 ± 29 | 48 ± 26 | 42 ± 32 | NS |
Rheumatoid factor (IU/I) | 275 ± 341 | 423 ± 1103 | 68 ± 63 | NS |
Matrix metalloproteinase | 296 ± 302 | 302 ± 371 | 192 ± 139 | NS |
Disease activity 28 ESR | 5.8 ± 0.7 | 5.7 ± 0.8 | 5.3 ± 0.9 | NS |
Prednisone (mg) | 1.3 ± 2.6 | 1.5 ± 3.8 | 2.9 ± 2.7 | NS |
Patients on prednisone (%) | 60.4 (32/53) | 47.4 (18/38) | 100 (22/22) | 0.05 |
Tacrolimus (mg) | 2.1 ± 0.8 | 2.0 ± 0.8 | 1.9 ± 0.8 | NS |
P-glycoprotein expression on CD4 (molecule/cell) | 140 ± 58 | 159 ± 65 | 248 ± 110 | 0.05 |
P-glycoprotein expression on CD19 (molecule/cell) | 374 ± 171 | 388 ± 173 | 586 ± 193 | 0.05 |
C/M ratio | 0.49 ± 0.12 | 0.49 ± 0.17 | 0.36 ± 0.12 | 0.01 |
C/M: cell/medium. NS: nonsignificant.